The role of herpes simplex virus thymidine kinase in the treatment of solid tumours

Bibliography

• VILE RG, HART IR: In vitro and in vivo targeting of geneexpression to melanoma cells. Cancer Res. (1993) 53:962–967.
   PubMed Web of Science ®Google Scholar
• RIEGMAN PH, VLIETSTRA RJ, VAN DER KORPUT JA,BRINKMANN AO, TRAPMAN J: The promoter of the prostate-specific antigen gene contains a functional androgen responsive element. Mol. Endocrinol. (1991) 5:1921–1930.
   PubMed Web of Science ®Google Scholar
• PANG S, TANEJA S, DARDASHTI K et al.: Prostate tissue specificity of the prostate-specific antigen promoter isolated from a patient with prostate cancer. Hum. Gene Ther. (1995) 6:1417–1426.
   PubMed Web of Science ®Google Scholar
• MOOLTEN FL: Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res. (1986) 46:5276–5281.
   PubMed Web of Science ®Google Scholar
• ••This paper originally describes the suicide gene concept.
   Google Scholar
• FURMAN PA, MCGUIRT PV, KELLER PM, FYFE JA, ELIONGB: Inhibition by acyclovir of cell growth and DNA synthesis of cells biochemically transformed with herpesvirus genetic information. Virology (1980) 102:420–430.
   PubMed Web of Science ®Google Scholar
• CULVER KW, RAM Z, WALLBRIDGE S et al.: In vivo genetransfer with retroviral vector-producer cells for treatment of experimental brain tumors [see comments]. Science (1992) 256:1550–1552.
   PubMed Web of Science ®Google Scholar
• SMYTHE WR, HWANG HC, ELSHAMI AA et al.: Treatment of experimental human mesothelioma using adenovirus transfer of the herpes simplex thymidine kinase gene. Ann. Surg. (1995) 222:78–86.
   PubMed Web of Science ®Google Scholar
• MARINI FC, PAN BF, NELSON JA, LAPEYRE JN: The drug verapamil inhibits bystander killing but not cell suicide in thymidine kinase-ganciclovir prodrug-activated gene therapy. Cancer Gene Ther. (1996) 3 :405–412.
   PubMed Web of Science ®Google Scholar
• VILE RG, NELSON JA, CASTLEDEN S, CHONG H, HART IR: Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res. (1 9 9 4) 54:6228-6234.
   Google Scholar
• ••Paper showing the necessity of immune competence for thebystander effect.
   Google Scholar
• FREEMAN SM, ABBOUD CN, WHARTENBY KA et al.: The 'bystander effect': tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. (1993) 53:5274–5283.
   PubMed Web of Science ®Google Scholar
• •Initial attempt at analysis of the bystander effect with respect to cytokine production.
   Google Scholar
• RAM Z, WALBRIDGE S, SHAWKER T et al.: The effect of thymidine kinase transduction and ganciclovir therapy on tumor vasculature and growth of 9L gliomas in rats. J. Neurosurg. (1994) 81:256–260.
   PubMed Web of Science ®Google Scholar
• KIANMANESH AR, PERRIN H, PANIS Y et al.: A 'distant' bystander effect of suicide gene therapy: regression of nontransduced tumors together with a distant transduced tumor [see comments]. Hum. Gene Ther. (1997) 8:1807–1814.
   PubMed Web of Science ®Google Scholar
• •An interesting paper looking at tumours in different sites and the transmission of the bystander effect.
   Google Scholar
• GAGANDEEP S, BREW R, GREEN B et al.: Prodrug- activated gene therapy: involvement of an immuno-logical component in the 'bystander effect'. Cancer Gene Ther. (1996) 3:83–88.
   PubMed Web of Science ®Google Scholar
• LODISH H, BALTIMORE D, BERK A, ZIPURSKY SL, MATSUDAIRA P, DARNELL JE: Molecular Cell Biology, 3rd Edition. Lodish H, Baltimore D, Berk A, Zipursky SL, Matsudaira P, Darnell JE (Eds.), Scientific American Books (1995):1157–1159.
   Google Scholar
• BI WL, PARYSEK LM, WARNICK R, STAMBROOK PJ: In vitro evidence that metabolic cooperation is respon-sible for the bystander effect observed with HSV tk retroviral gene therapy. Hum. Gene Ther. (1993) 4:725–731.
   PubMed Web of Science ®Google Scholar
• DENNING C, PITTS JD: Bystander effects of different enzyme-prodrug systems for cancer gene therapy depend on different pathways for intercellular transfer of toxic metabolites, a factor that will govern clinical choice of appropriate regimes [see comments]. Hum. Gene Ther. (1997) 8:1825–1835.
   PubMed Web of Science ®Google Scholar
• ••Good evidence of the function of gap junctions.
   Google Scholar
• NAUS CC, ELISEVICH K, ZHU D, BELLIVEAU DJ, DEL MR: In vivo growth of C6 glioma cells transfected with connexin43 cDNA. Cancer Res. (1992) 52:4208–4213.
   PubMed Web of Science ®Google Scholar
• ELSHAMI AA, SAAVEDRA A, ZHANG H et al.: Gap junctions play a role in the 'bystander effect' of the herpes simplex virus thymidine kinase/ganciclovir system in vitro. Gene Ther. (1996) 3:85–92.
   PubMed Web of Science ®Google Scholar
• BLADES RA, KEATING PJ, MCWILLIAM LJ, GEORGE NJ, STERN PL: Loss of HLA class I expression in prostate cancer: implications for immunotherapy. Urology (1995) 46:681–686.
   PubMed Web of Science ®Google Scholar
• RESTIFO NP, KAWAKAMI Y, MARICOLA F eta].: Molecular mechanisms of escape of tumor recognition: immuno-genetherapy and the cell biology of MHC class I. J. Immunother. 142:182–190.
   Google Scholar
• HUANG RP, FAN Y, HOSSAIN MZ et al.: Reversion of the neoplastic phenotype of human glioblastoma cells by connexin 43 (cx43). Cancer Res. (1998) 58:5089–5096.
   PubMed Web of Science ®Google Scholar
• YANG L, CHIANG Y, LENZ HJ et al.: Intercellular communication mediates the bystander effect during herpes simplex thymidine kinase/ganciclovir-based gene therapy of human gastrointestinal tumor cells. Hum. Gene Ther. (1998) 9:719–728.
   PubMed Web of Science ®Google Scholar
• ROSOLEN A, FRASCELLA E, DI FC et al.: In vitro and in vivo antitumor effects of retrovirus-mediated herpes simplex thymidine kinase gene-transfer in human medulloblastoma. Gene Ther. (1998) 5:113–120.
   PubMed Web of Science ®Google Scholar
• MCMASTERS RA, SAYLORS RL, JONES KE et al.: Lack of bystander killing in herpes simplex virus thymidine kinase- transduced colon cell lines due to deficient connexin43 gap junction formation. Hum. Gene Ther. (1998) 9:2253–2261.
   PubMed Web of Science ®Google Scholar
• IMAIZUMI K, HASEGAWA Y, KAWABE T et al.: Bystander tumoricidal effect and gap junctional communication in lung cancer cell lines. Am. J. Respir. Cell Mol. (1998) 18:205–212.
   Web of Science ®Google Scholar
• PARK JY, ELSHAMI AA, AMIN K et al.: Retinoids augment the bystander effect in vitro and in vivo in herpes simplex virus thymidine kinase/ganciclovir-mediated gene therapy. Gene Ther. (1997) 4:909–917.
   PubMed Web of Science ®Google Scholar
• TOURAINE RL, VAHANIAN N, RAMSEY WJ, BLAESE RM: Enhancement of the herpes simplex virus thymidine kinase/ganciclovir bystander effect and its antitumor efficacy in vivoby pharmacologic manipulation of gap junctions. Hum. Gene Ther. (1998) 9:2385–2391.
   PubMed Web of Science ®Google Scholar
• MEHTA PP, LOKESHWAR BL, SCHILLER PC et al.: Gap-junctional communication in normal and neoplastic prostate epithelial cells and its regulation by cAMP. Mol. Carcinog. (1996) 15:18–32.
   PubMed Web of Science ®Google Scholar
• DUFLOT-DANCER A, PICCOLI C, ROLLAND A, YAMASAKI H, MESNIL M: Long-term connexin-mediated bystander effect in highly tumorigenic human cells in vivo in herpes simplex virus thymidine kinase/ganciclovir gene therapy. Gene Ther. (1998) 5:1372–1378.
   PubMed Web of Science ®Google Scholar
• PAVLOVIC J, NAWRATH M, TU R, HEINICKE T, MOELLING K: Anti-tumor immunity is involved in the thymidine kinase-mediated killing of tumors induced by activated Ki-ras(G12V). Gene Ther. (1996) 3:635–643.
   PubMed Web of Science ®Google Scholar
• CARUSO M, PANTS Y, GAGANDEEP S et al.: Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc. Natl. Acad. Sci. USA (1993) 90:7024–7028.
   PubMed Web of Science ®Google Scholar
• FREEMAN SM, RAMESH R, SHASTRI M et al: The role of cytokines in mediating the bystander effect using HSV-TK xenogeneic cells. Cancer Lett. (1995) 92:167–174.
   PubMed Web of Science ®Google Scholar
• RAMESH R, MARROGI AJ, MUNSHI A, ABBOUD CN, FREEMAN SM: In vivo analysis of the 'bystander effect': a cytokine cascade. Exp. Hematol. (1996) 24:829–838.
   PubMed Web of Science ®Google Scholar
• FREEMAN SM, RAMESH R, MARROGI AJ: Immune system in suicide-gene therapy. Lancet (1997) 349:2–3.
   PubMed Web of Science ®Google Scholar
• ••Excellent brief overview of suicide gene therapy and theimmune system.
   Google Scholar
• VILE RG, CASTLEDEN S, MARSHALL J et al.: Generation of an anti-tumour immune response in a non-immunogenic tumour: HSVtk killing in vivo stimulates a mononuclear cell infiltrate and a Thl-like profile of intratumoural cytokine expression. Int. J. Cancer (1997) 71:267–274.
   PubMed Web of Science ®Google Scholar
• MULLEN CA, ANDERSON L, WOODS K, NISHINO M, PETROPOULOS D: Ganciclovir chemoablation of herpes thymidine kinase suicide gene- modified tumors produces tumor necrosis and induces systemic immune responses. Hum. Gene Ther. (1998) 9:2019–2030.
   PubMed Web of Science ®Google Scholar
• LUCEY DR, CLERICI M, SHEARER GM: Type 1 and Type 2cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases. Clin. Microbiol. Rev. (1996) 9:532–562.
   PubMed Web of Science ®Google Scholar
• PELLEGRINI P, BERGHELLA AM, DEL BT et al.: Disregula-tion in Till and TH2 subsets of CD4+ T cells in periph-eral blood of colorectal cancer patients and involvement in cancer establishment and progres-sion. Cancer Immunol. Immunother. (1996) 42:1–8.
   PubMed Web of Science ®Google Scholar
• SATO M, GOTO S, KANEKO R et al.: Impaired production of Thl cytokines and increased frequency of Th2 subsets in PBMC from advanced cancer patients. Anti-Cancer Res. (1998) 18:3951–3955.
   PubMed Web of Science ®Google Scholar
• LOWES MA, BISHOP GA, CROTTY K, BARNETSON RS, HALLIDAY GM: T helper 1 cytokine mRNA is increased in spontaneously regressing primary melanomas. J. Invest. Dermatol. (1997) 108:914–919.
   PubMed Web of Science ®Google Scholar
• WAGNER SN, SCHULTEWOLTER T, WAGNER C et al: Immune response against human primary malignant melanoma: a distinct cytokine mRNA profile associ-ated with spontaneous regression. Lab. Invest. (1998) 78:541–550.
   PubMed Web of Science ®Google Scholar
• WU TC, HUANG AY, JAFFEE EM, LEVITSKY HI, PARDOLL DM: A reassessment of the role of B7-1 expression in tumor rejection. J. Exp. Med. (1995) 182:1415–1421.
   PubMed Web of Science ®Google Scholar
• RAMESH R, MUNSHI A, ABBOUD CN, MARROGI AJ, FREEMAN SM: Expression of costimulatory molecules: B7 and ICAM up-regulation after treatment with a suicide gene. Cancer Gene Ther. (1996) 3:373–384.
   PubMed Web of Science ®Google Scholar
• LENSCHOW DJ, HEROLD KC, RHEE L et al.: CD28/B7 regulation of Thl and Th2 subsets in the development of autoimmune diabetes [published erratum appears in Immunity 1997 Feb;6(2):following 215]. Immunity (1996) 5:285–293.
   PubMed Web of Science ®Google Scholar
• BI W, KIM YG, FELICIANO ES et al.: An HSVtk-mediated local and distant antitumor bystander effect in tumors of head and neck origin in athymic mice. Cancer Gene Ther. (1997) 4:246–252.
   PubMed Web of Science ®Google Scholar
• YAMAMOTO S, SUZUKI S, HOSHINO A, AKIMOTO M, SHIMADA T: Herpes simplex virus thymidine kinase/ganciclovir-mediated killing of tumor cell induces tumor-specific cytotoxic T cells in mice. Cancer Gene Ther. (1997) 4:91–96.
   PubMed Web of Science ®Google Scholar
• HALL SJ, SANFORD MA, ATKINSON G, CHEN SH: Induction of potent antitumor natural killer cell activity by herpes simplex virus-thymidine kinase and ganciclovir therapy in an orthotopic mouse model of prostate cancer. Cancer Res. (1998) 58:3221–3225.
   PubMed Web of Science ®Google Scholar
• COLOMBO BM, BENEDETTI S, OTTOLENGHI S et al: The 'bystander effect': association of U-87 cell death with ganciclovir- mediated apoptosis of nearby cells and lack of effect in athymic mice. Hum. Gene Ther. (1995) 6:763–772.
   PubMed Web of Science ®Google Scholar
• HAMEL W, MAGNELLI L, CHIARUGI VP, ISRAEL MA: Herpes simplex virus thymidine kinase/ganciclovir-mediated apoptotic death of bystander cells. Cancer Res. (1996) 56:2697–2702.
   PubMed Web of Science ®Google Scholar
• CRAPERI D, VICAT JM, NISSOU MF et al.: Increased baxexpression is associated with cell death induced by ganciclovir in a herpes thymidine kinase gene-expressing glioma cell line [In Process Citation]. Hum. Gene Ther. (1999) 10:679–688.
   PubMed Web of Science ®Google Scholar
• ROVERE P, VALLINOTO C, BONDANZA A et al.: Bystander apoptosis triggers dendritic cell maturation and antigen-presenting function. J. Immune]. (1998) 161:4467–4471.
   PubMed Web of Science ®Google Scholar
• MELCHER A, TODRYK S, HARDWICK N et al: Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expres-sion. Nature Med. (1998) 4:581–587.
   PubMed Web of Science ®Google Scholar
• RAMESH R, MUNSHI A, MARROGI AJ, FREEMAN SM: Enhancement of tumor killing using a combination of tumor immunization and HSV-tk suicide gene therapy. Int. J. Cancer (1999) 80:380–386.
   PubMed Web of Science ®Google Scholar
• BENEDETTI S, DIMECO F, POLLO B etal.: Limited efficacy of the HSV-TK/GCV system for gene therapy of malignant gliomas and perspectives for the combined transduction of the interleukin-4 gene. Hum. Gene Ther. (1997) 8:1345–1353.
   Google Scholar
• COLL JL, MESNIL M, LEFEBVRE MF, LANCON A, FAVROT MC: Long-term survival of immunocompetent rats with intraperitoneal colon carcinoma tumors using herpes simplex thymidine kinase/ganciclovir and IL-2 treatments. Gene Ther. (1997) 4:1160–1166.
   PubMed Web of Science ®Google Scholar
• CASTLEDEN SA, CHONG H, GARCIA-RIBAS I et al.: A family of bicistronic vectors to enhance both local and systemic antitumor effects of HSVtk or cytokine expression in a murine melanoma model. Hum. Gene Ther. (1997) 8:2087–2102.
   PubMed Web of Science ®Google Scholar
• EASTHAM JA, CHEN SH, SEHGAL I et al.: Prostate cancer gene therapy: herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models. Hum. Gene Ther. (1996) 7:515–523.
   PubMed Web of Science ®Google Scholar
• HALL SJ, MUTCHNIK SE, CHEN SH, WOO SL, THOMPSON TC: Adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy leads to systemic activity against spontaneous and induced metastasis in an orthotopic mouse model of prostate cancer. Int. J. Cancer (1997) 70:183–187.
   PubMed Web of Science ®Google Scholar
• ROSENBERG SA, BLAESE RM, BRENNER MK et al.: Human gene marker/therapy clinical protocols. Hum. Gene Ther. (1997) 8:2301–2338.
   PubMedGoogle Scholar
• VAN DER EB MM, CRAMER SJ, VERGOUWE Y et al.: Severe hepatic dysfunction after adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene and ganciclovir administration. Gene Ther. (1998) 5:451–458.
   Google Scholar
• BRAND K, LOSER P, ARNOLD W, BARTELS T, STRAUSS M: Tumor cell-specific transgene expression prevents liver toxicity of the adeno-HSVtk/GCV approach [In Process Citation]. Gene Ther. (1998) 5:1363–1371.
   PubMed Web of Science ®Google Scholar
• FREYTAG SO, ROGULSKI KR, PAIELLI DL, GILBERT JD, KIM JH: A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy [see comments]. Hum. Gene Ther. (1998) 9:1323–1333.
   PubMed Web of Science ®Google Scholar
• WILDNER 0, BLAESE RM, MORRIS JC: Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase. Cancer Res. (1999) 59:410–413.
   PubMed Web of Science ®Google Scholar
• WILDNER 0, MORRIS JC, VAHANIAN N et al.: Adenoviral vectors capable of replication improve the efficacy of HSVtk/GCV suicide gene therapy of cancer. Gene Ther. (1999) 6:57–62.
   Google Scholar
• MORTON DL, FOSHAG LJ, HOON DS et al.: Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine [published erratum appears in Ann Surg 1993 Mar;217(3):309]. Ann. Surg. (1992) 216:463-482. Matthew JA Perryt, Stephen M Todryk .3,E Angus G Dalgleish tAuthor for correspondence Urology Research Fellow, Departments of Urology and Oncology, St George's Hospital Medical School, Cranmer Terrace, London SW17 0QT, UK Tel.: +44 181 725 5815; Fax: +44 181 725 0158; Email: [email protected]
   Google Scholar